Samantha Shams is an Oncology physician affiliated with Piedmont Cancer Institute. OpenAlex indexes 14 publications with 266 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1800 Howell Mill Rd NW Ste 800
Atlanta, GA 30318
Telephone
404-350-9853Provider last certified this registry record 23 Mar 2023.
Industry payments
64 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Stemline Therapeutics Inc.Program year20251 payment
- ABBVIE INC.Program year20258 payments
- Novartis Pharmaceuticals CorporationProgram year20259 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
75.9%Erythropoiesis-stimulating Agent59.9%Darbepoetin alfa100%Part B, office-administered≥11 patientsIron, parenteral preparations15.5%Ferric derisomaltose100%Part B, office-administered≥14 patients+ 1 more class in this area
Musculoskeletal
16.4%RANK Ligand Inhibitor16.4%Denosumab100%Part B, office-administered≥13 patientsSensory organs
4.1%Corticosteroid4.1%Dexamethasone sodium phosphate96%Dexamethasone4%Part D + Part B<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update
Journal of Clinical Oncology
2025 - Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Clinical Insights
JCO Oncology Practice
2025
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”